Voltz R, Hohlfeld R, Fateh-Moghadam A, Witt T N, Wick M, Reimers C, Siegele B, Wekerle H
Department of Neuroimmunology, Max-Planck-Institute, Martinsried, Germany.
Neurology. 1991 Nov;41(11):1836-8. doi: 10.1212/wnl.41.11.1836.
Anti-acetylcholine receptor (AChR) antibodies in myasthenia gravis (MG) can be quantitated using AChR extracted from the human rhabdomyosarcoma cell line TE671 (AChRTE671) as a practical alternative to AChR from human amputated limbs (AChRAMP). We compared the two antigen preparations using serum samples from different clinical groups of MG patients (n = 112) and various controls (n = 189). With two exceptions, both tests were positive or negative in the same patients. However, in the generalized MG group, the TE671 assay yielded significantly lower titers than the AChRAMP assay.
重症肌无力（MG）患者体内的抗乙酰胆碱受体（AChR）抗体可以使用从人横纹肌肉瘤细胞系TE671提取的AChR（AChRTE671）进行定量检测，这是一种切实可行的替代方法，可替代从人截肢肢体提取的AChR（AChRAMP）。我们使用来自MG患者不同临床组（n = 112）和各种对照组（n = 189）的血清样本，对这两种抗原制剂进行了比较。除两个例外情况外，同一患者的两种检测结果均为阳性或阴性。然而，在全身型MG组中，TE671检测法产生的滴度明显低于AChRAMP检测法。
